This approach not only facilitates chemotherapy drug delivery, enhances the anti-tumor response to gemcitabine or fluorouracil, and significantly increases intratumoral effector T cells when the CD93 pathway is inhibited, rendering mouse tumors more responsive to immune checkpoint treatment. The gene discussed is CD93; the disease is neoplasm.